
Lutgarde Lynen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1044953/publications.pdf Version: 2024-02-01



LUTCARDELVNEN

#	Article	IF	CITATIONS
1	Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study. International Health, 2023, 15, 258-264.	2.0	1
2	Pretomanid for tuberculosis: a systematic review. Clinical Microbiology and Infection, 2022, 28, 31-42.	6.0	30
3	Community-Based ART Service Delivery for Key Populations in Sub-Saharan Africa: Scoping Review of Outcomes Along the Continuum of HIV Care. AIDS and Behavior, 2022, 26, 2314-2337.	2.7	7
4	Person entred care and short oral treatment for rifampicinâ€resistant tuberculosis improve retention in care in Kandahar, Afghanistan. Tropical Medicine and International Health, 2022, 27, 207-215.	2.3	2
5	Virological outcomes and risk factors for non-suppression for routine and repeat viral load testing after enhanced adherence counselling during viral load testing scale-up in Zimbabwe: analytic cross-sectional study using laboratory data from 2014 to 2018. AIDS Research and Therapy, 2022, 19, .	1.7	5
6	High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss. European Respiratory Journal, 2021, 57, 2002250.	6.7	12
7	Comparison of first-line tuberculosis treatment outcomes between previously treated and new patients: a retrospective study in Machakos subcounty, Kenya. International Health, 2021, 13, 272-280.	2.0	8
8	Time of administration of rabies immunoglobulins and adequacy of antibody response upon post-exposure prophylaxis: a descriptive retrospective study in Belgium. Acta Clinica Belgica, 2021, 76, 91-97.	1.2	4
9	Hepatitis C Prevalence and Validation of a Clinical Prediction Score for Targeted Screening among People Living with HIV in Ghana. Journal of the International Association of Providers of AIDS Care, 2021, 20, 232595822110224.	1.5	1
10	Finding the right balance between efficacy and tolerability for TB treatment: the search continues. International Journal of Tuberculosis and Lung Disease, 2021, 25, 84-86.	1.2	1
11	Case Report: Therapeutic Threshold for Rifampicin-Resistant Tuberculosis in a Patient from Maputo, Mozambique. American Journal of Tropical Medicine and Hygiene, 2021, 104, 1317-1320.	1.4	2
12	Diagnostic Accuracy of the INSHI Consensus Case Definition for the Diagnosis of Paradoxical Tuberculosis-IRIS. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 587-592.	2.1	6
13	Predictors of virological failure among people living with HIV receiving first line antiretroviral treatment in Myanmar: retrospective cohort analysis. AIDS Research and Therapy, 2021, 18, 16.	1.7	13
14	Human rights: finding the right balance for rifampicin-resistant TB treatment. International Journal of Tuberculosis and Lung Disease, 2021, 25, 327-328.	1.2	0
15	Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis (PReGo): a randomised, placebo-controlled, crossover trial. Lancet Infectious Diseases, The, 2021, 21, 657-667.	9.1	29
16	Development of a risk score to guide targeted hepatitis C testing among human immunodeficiency virus patients in Cambodia. World Journal of Hepatology, 2021, 13, 1167-1180.	2.0	0
17	Long-term retention and predictors of attrition for key populations receiving antiretroviral treatment through community-based ART in Benue State Nigeria: A retrospective cohort study. PLoS ONE, 2021, 16, e0260557.	2.5	3
18	Temporary disengagement and re-engagement in human immunodeficiency virus care in a rural county serving pastoralist communities in Kenya: a retrospective cohort study. International Health, 2020, 12, 95-100.	2.0	6

#	Article	IF	CITATIONS
19	Retention and predictors of attrition among patients who started antiretroviral therapy in Zimbabwe's national antiretroviral therapy programme between 2012 and 2015. PLoS ONE, 2020, 15, e0222309.	2.5	21
20	Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study. PLoS ONE, 2020, 15, e0237355.	2.5	8
21	District-level strategies to control the HIV epidemic in Zimbabwe: a practical example of precision public health. BMC Research Notes, 2020, 13, 393.	1.4	3
22	Translating drug resistant tuberculosis treatment guidelines to reality in war-torn Kandahar, Afghanistan: A retrospective cohort study. PLoS ONE, 2020, 15, e0237787.	2.5	7
23	The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance. PLoS ONE, 2020, 15, e0233500.	2.5	16
24	First-line tuberculosis treatment with double-dose rifampicin is well tolerated. International Journal of Tuberculosis and Lung Disease, 2020, 24, 499-505.	1.2	11
25	Challenges to Differentiate Hepatitis C Genotype 1 and 6: Results from A Field-Study in Cambodia. Infectious Diseases and Therapy, 2020, 9, 657-667.	4.0	0
26	Comparison of predictive models for hepatitis C co-infection among HIV patients in Cambodia. BMC Infectious Diseases, 2020, 20, 209.	2.9	3
27	High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1578-1579.	5.6	8
28	False Rifampicin Resistance in Xpert Ultra Applied to Lymph Node Aspirate: A Case Report. Open Forum Infectious Diseases, 2020, 7, ofaa204.	0.9	1
29	Tuberculosis treatment: one-shot approach or cascade of regimens?. Lancet Respiratory Medicine,the, 2020, 8, e4-e5.	10.7	7
30	The effect of HIV-associated tuberculosis, tuberculosis-IRIS and prednisone on lung function. European Respiratory Journal, 2020, 55, 1901692.	6.7	15
31	Decision-making in the diagnosis of tuberculous meningitis. Wellcome Open Research, 2020, 5, 11.	1.8	8
32	Patient-mix, programmatic characteristics, retention and predictors of attrition among patients starting antiretroviral therapy (ART) before and after the implementation of HIV "Treat All―in Zimbabwe. PLoS ONE, 2020, 15, e0240865.	2.5	13
33	Title is missing!. , 2020, 15, e0222309.		0
34	Title is missing!. , 2020, 15, e0222309.		0
35	Title is missing!. , 2020, 15, e0222309.		0

#	Article	IF	CITATIONS
37	Title is missing!. , 2020, 15, e0237355.		0
38	Title is missing!. , 2020, 15, e0237355.		0
39	Title is missing!. , 2020, 15, e0237355.		0
40	Title is missing!. , 2020, 15, e0237355.		0
41	Performance of algorithms for tuberculosis active case finding in underserved high-prevalence settings in Cambodia: a cross-sectional study. Global Health Action, 2019, 12, 1646024.	1.9	6
42	Viral load detection and management on first line ART in rural Rwanda. BMC Infectious Diseases, 2019, 19, 8.	2.9	15
43	Effect of reliance on Xpert MTB/RIF on time to treatment and multidrug-resistant tuberculosis treatment outcomes in Tanzania: a retrospective cohort study. International Health, 2019, 11, 520-527.	2.0	7
44	Comment on: Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study. Journal of Antimicrobial Chemotherapy, 2018, 73, 1733-1734.	3.0	2
45	What Is the Role of Paired Rapid Plasma Reagin Testing (Simultaneous Testing of Acute and) Tj ETQq1 1 0.784314 Transmitted Diseases, 2018, 45, 35-38.	4 rgBT /Ov 1.7	verlock 10 7
46	Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. New England Journal of Medicine, 2018, 379, 1915-1925.	27.0	139
47	The Immune Mechanisms of Lung Parenchymal Damage in Tuberculosis and the Role of Host-Directed Therapy. Frontiers in Microbiology, 2018, 9, 2603.	3.5	56
48	Development of a clinical prediction score for targeted hepatitis C screening in a low-risk HIV cohort in Cambodia. Journal of Hepatology, 2018, 68, S177-S178.	3.7	1
49	Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs. International Journal of Tuberculosis and Lung Disease, 2018, 22, 239-245.	1.2	65
50	CD4 results with a bias larger than hundred cells per microliter can have a significant impact on the clinical decision during treatment initiation of HIV patients. Cytometry Part B - Clinical Cytometry, 2017, 92, 476-484.	1.5	9
51	Performance of the Antiretroviral Treatment Program in Ethiopia, 2005-2015: strengths and weaknesses toward ending AIDS. International Journal of Infectious Diseases, 2017, 60, 70-76.	3.3	34
52	Diagnosis of Visceral Leishmaniasis Using Peripheral Blood Microscopy in Ethiopia: A Prospective Phase-III Study of the Diagnostic Performance of Different Concentration Techniques Compared to Tissue Aspiration. American Journal of Tropical Medicine and Hygiene, 2017, 96, 190-196.	1.4	12
53	A cross-sectional study of hepatitis C among people living with HIV in Cambodia: Prevalence, risk factors, and potential for targeted screening. PLoS ONE, 2017, 12, e0183530.	2.5	23
54	Rational use of Xpert testing in patients with presumptive TB: clinicians should be encouraged to use the test-treat threshold. BMC Infectious Diseases, 2017, 17, 674.	2.9	8

#	Article	IF	CITATIONS
55	Unexpected Infection with <i>Armillifer</i> Parasites. Emerging Infectious Diseases, 2017, 23, 2116-2118.	4.3	7
56	Development and external validation of a clinical prognostic score for death in visceral leishmaniasis patients in a high HIV co-infection burden area in Ethiopia. PLoS ONE, 2017, 12, e0178996.	2.5	5
57	Ten year experience with antiretroviral treatment in Cambodia: Trends in patient characteristics and treatment outcomes. PLoS ONE, 2017, 12, e0185348.	2.5	4
58	Electrolyte and Metabolic Disturbances in Ebola Patients during a Clinical Trial, Guinea, 2015. Emerging Infectious Diseases, 2016, 22, .	4.3	13
59	Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint. Tropical Medicine and International Health, 2016, 21, 1490-1495.	2.3	3
60	Organizing the Donation of Convalescent Plasma for a Therapeutic Clinical Trial on Ebola Virus Disease: The Experience in Guinea. American Journal of Tropical Medicine and Hygiene, 2016, 95, 647-653.	1.4	10
61	Usefulness of Common Fibrosis Markers to Predict Viremia in Patients with Reactive Hepatitis C Antibody Test. Journal of Hepatology, 2016, 64, S715-S716.	3.7	1
62	Design and analysis considerations in the Ebola_Tx trial evaluating convalescent plasma in the treatment of Ebola virus disease in Guinea during the 2014–2015 outbreak. Clinical Trials, 2016, 13, 13-21.	1.6	17
63	Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. New England Journal of Medicine, 2016, 374, 33-42.	27.0	457
64	The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field. Clinical Infectious Diseases, 2016, 62, 69-74.	5.8	84
65	Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial). JMIR Research Protocols, 2016, 5, e173.	1.0	10
66	Factors associated with prevalent tuberculosis among patients receiving highly active antiretroviral therapy in a Nigerian tertiary hospital. Annals of Medical and Health Sciences Research, 2016, 6, 120.	0.8	7
67	Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. Tropical Medicine and International Health, 2015, 20, 1823-1831.	2.3	17
68	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 414-419.	2.1	17
69	Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study. PLoS Neglected Tropical Diseases, 2015, 9, e0004087.	3.0	53
70	Advanced HIV Disease at Enrolment in HIV Care: Trends and Associated Factors over a Ten Year Period in Cambodia. PLoS ONE, 2015, 10, e0143320.	2.5	9
71	Impact of the Use of a Rapid Diagnostic Test for Visceral Leishmaniasis on Clinical Practice in Ethiopia: A Retrospective Study. PLoS Neglected Tropical Diseases, 2015, 9, e0003738.	3.0	17
72	Clinical aspects of paediatric visceral leishmaniasis in <scp>N</scp> orthâ€west <scp>E</scp> thiopia. Tropical Medicine and International Health, 2015, 20, 8-16.	2.3	30

#	Article	IF	CITATIONS
73	Is frontloaded sputum microscopy an option in active tuberculosis case finding?. International Journal of Tuberculosis and Lung Disease, 2015, 19, 91-96.	1.2	4
74	Systematic screening for drug-resistant tuberculosis with Xpert [®] MTB/RIF in a referral hospital in Cambodia. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1528-1535.	1.2	8
75	Atypical manifestations of visceral leishmaniasis in patients with HIV in north Ethiopia: a gap in guidelines for the management of opportunistic infections in resource poor settings. Lancet Infectious Diseases, The, 2015, 15, 122-129.	9.1	31
76	Challenges from Tuberculosis Diagnosis to Care in Community-Based Active Case Finding among the Urban Poor in Cambodia: A Mixed-Methods Study. PLoS ONE, 2015, 10, e0130179.	2.5	45
77	Simplified Clinical Prediction Scores to Target Viral Load Testing in Adults with Suspected First Line Treatment Failure in Phnom Penh, Cambodia. PLoS ONE, 2014, 9, e87879.	2.5	13
78	Hepatitis B and C Co-Infection among HIV-Infected Adults while on Antiretroviral Treatment: Long-Term Survival, CD4 Cell Count Recovery and Antiretroviral Toxicity in Cambodia. PLoS ONE, 2014, 9, e88552.	2.5	48
79	Higher rates of metabolic syndrome among women taking zidovudine as compared to tenofovir in rural Africa: preliminary data from the CART-1 study. Journal of the International AIDS Society, 2014, 17, 19552.	3.0	4
80	High Parasitological Failure Rate of Visceral Leishmaniasis to Sodium Stibogluconate among HIV Co-infected Adults in Ethiopia. PLoS Neglected Tropical Diseases, 2014, 8, e2875.	3.0	64
81	Bacterial Sepsis in Patients with Visceral Leishmaniasis in Northwest Ethiopia. BioMed Research International, 2014, 2014, 1-7.	1.9	25
82	Visceral Leishmaniasis and HIV Coinfection in East Africa. PLoS Neglected Tropical Diseases, 2014, 8, e2869.	3.0	114
83	A Screen-and-Treat Strategy Targeting Visceral Leishmaniasis in HIV-Infected Individuals in Endemic East African Countries: The Way Forward?. PLoS Neglected Tropical Diseases, 2014, 8, e3011.	3.0	21
84	Visceral Leishmaniasis as an AIDS Defining Condition: Towards Consistency across WHO Guidelines. PLoS Neglected Tropical Diseases, 2014, 8, e2916.	3.0	14
85	Exploring three approaches to offer distance learning courses through a social network of health researchers in three African countries. , 2014, , .		1
86	How to improve patient retention in an antiretroviral treatment program in Ethiopia: a mixed-methods study. BMC Health Services Research, 2014, 14, 45.	2.2	29
87	Leishmaniasis in immunosuppressed individuals. Clinical Microbiology and Infection, 2014, 20, 286-299.	6.0	266
88	Scaling up antiretroviral treatment and improving patient retention in care: lessons from Ethiopia, 2005-2013. Globalization and Health, 2014, 10, 43.	4.9	51
89	Bacterial sepsis in patients with visceral leishmaniasis in Northwest Ethiopia. International Journal of Infectious Diseases, 2014, 21, 6.	3.3	0
90	A Clinical Prediction Score for Targeted Creatinine Testing Before Initiating Tenofovir-Based Antiretroviral Treatment in Cambodia. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, e150-e152.	2.1	2

#	Article	IF	CITATIONS
91	Community-Based Active Tuberculosis Case Finding in Poor Urban Settlements of Phnom Penh, Cambodia: A Feasible and Effective Strategy. PLoS ONE, 2014, 9, e92754.	2.5	88
92	Syphilis reinfections pose problems for syphilis diagnosis in Antwerp, Belgium – 1992 to 2012. Eurosurveillance, 2014, 19, 20958.	7.0	46
93	HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals. Lancet Infectious Diseases, The, 2013, 13, 251-259.	9.1	39
94	Rapid diagnostic tests for neurological infections in central Africa. Lancet Infectious Diseases, The, 2013, 13, 546-558.	9.1	47
95	Validation of a Clinical Prediction Score to Target Viral Load Testing in Adults With Suspected First-Line Treatment Failure in Resource-Constrained Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 509-516.	2.1	18
96	Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations Associated with First-Line Stavudine-Containing Antiretroviral Therapy: Programmatic Implications for Countries Phasing Out Stavudine. Journal of Infectious Diseases, 2013, 207, S70-S77.	4.0	30
97	Timing of antiretroviral therapy in Cambodian hospital after diagnosis of tuberculosis: impact of revised WHO guidelines. Bulletin of the World Health Organization, 2013, 91, 195-206.	3.3	8
98	Incidence and risk factors for tuberculosis in HIV-infected patients while on antiretroviral treatment in Cambodia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2013, 107, 235-242.	1.8	16
99	Bloodstream Infection among Adults in Phnom Penh, Cambodia: Key Pathogens and Resistance Patterns. PLoS ONE, 2013, 8, e59775.	2.5	47
100	Risk Factors of Treatment-Limiting Anemia after Substitution of Zidovudine for Stavudine in HIV-Infected Adult Patients on Antiretroviral Treatment. PLoS ONE, 2013, 8, e60206.	2.5	15
101	Azithromycin and Ciprofloxacin Resistance in Salmonella Bloodstream Infections in Cambodian Adults. PLoS Neglected Tropical Diseases, 2012, 6, e1933.	3.0	60
102	Antiretroviral treatment in low-resource settings: what has changed in the last 10 years and what needs to change in the coming years?. Expert Review of Anti-Infective Therapy, 2012, 10, 1287-1296.	4.4	5
103	Nontuberculous Mycobacterial Disease in Patients with HIV in Southeast Asia. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 981-988.	5.6	52
104	Staphylococcus aureus blood stream infections in Cambodian adults. International Journal of Infectious Diseases, 2012, 16, e437.	3.3	0
105	Is increasing complexity of algorithms the price for higher accuracy? virtual comparison of three algorithms for tertiary level management of chronic cough in people living with HIV in a low-income country. BMC Medical Informatics and Decision Making, 2012, 12, 2.	3.0	3
106	Pretreatment HIV-1 drug resistance testing in sub-Saharan Africa. Lancet Infectious Diseases, The, 2012, 12, 911.	9.1	2
107	Short and long term retention in antiretroviral care in health facilities in rural Malawi and Zimbabwe. BMC Health Services Research, 2012, 12, 444.	2.2	23
108	A Clinical Prediction Score in Addition to WHO Criteria for Anti-Retroviral Treatment Failure in Resource-Limited Settings - Experience from Lesotho. PLoS ONE, 2012, 7, e47937.	2.5	15

#	Article	IF	CITATIONS
109	Adoption of new HIV treatment guidelines and drug substitutions within firstâ€line as a measure of quality of care in rural Lesotho: health centers and hospitals compared. Tropical Medicine and International Health, 2012, 17, 1245-1254.	2.3	15
110	Incidence of Treatment-Limiting Toxicity with Stavudine-Based Antiretroviral Therapy in Cambodia: A Retrospective Cohort Study. PLoS ONE, 2012, 7, e30647.	2.5	34
111	Genotypic Impact of Prolonged Detectable HIV Type 1 RNA Viral Load after HAART Failure in a CRF01_AE-Infected Cohort. AIDS Research and Human Retroviruses, 2011, 27, 727-735.	1.1	14
112	Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet, The, 2011, 378, 282-284.	13.7	212
113	Development and validation of systems for rational use of viral load testing in adults receiving first-line ART in sub-Saharan Africa. Aids, 2011, 25, 1627-1635.	2.2	27
114	Melioidosis, Phnom Penh, Cambodia. Emerging Infectious Diseases, 2011, 17, 1289-1292.	4.3	32
115	Determination of Kidney Function Before Tenofovir Initiation: Four-Fold Difference in Need of Tenofovir Dose Reduction Depending on Method Used. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, e21-e23.	2.1	3
116	Challenges in developing national HIV guidelines: experience from the eastern Mediterranean. Bulletin of the World Health Organization, 2011, 89, 442-450.	3.3	4
117	A telemedicine service for HIV/AIDS physicians working in developing countries. Journal of Telemedicine and Telecare, 2011, 17, 65-70.	2.7	28
118	Evaluation of the 2007 WHO Guideline to Improve the Diagnosis of Tuberculosis in Ambulatory HIV-Positive Adults. PLoS ONE, 2011, 6, e18502.	2.5	32
119	Performance of Abdominal Ultrasound for Diagnosis of Tuberculosis in HIV-Infected Persons Living in Cambodia. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 500-502.	2.1	23
120	PREVALENCE OF CHRONIC RENAL FAILURE STAGE 3 OR MORE IN HIV-INFECTED PATIENTS IN ANTWERP: AN OBSERVATIONAL STUDY. Acta Clinica Belgica, 2010, 65, 392-398.	1.2	4
121	Monitoring for treatment failure in patients on first-line antiretroviral treatment in resource-constrained settings. Current Opinion in HIV and AIDS, 2010, 5, 1-5.	3.8	39
122	Attrition of HIV-infected individuals not yet eligible for antiretroviral treatment: do we care?. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2010, 104, 690-692.	1.8	5
123	Mobile learning for HIV/AIDS healthcare worker training in resource-limited settings. AIDS Research and Therapy, 2010, 7, 35.	1.7	53
124	Decrease of vitamin D concentration in patients with HIV infection on a Non Nucleoside Reverse Transcriptase Inhibitor containing regimen. AIDS Research and Therapy, 2010, 7, 40.	1.7	50
125	Challenges in HIV and visceral Leishmania co-infection: future research directions. Tropical Medicine and International Health, 2010, 15, 1266-1267.	2.3	12
126	Challenges in the diagnosis of meningitis in low-resource settings. Tropical Medicine and International Health, 2010, 15, 1556-1557.	2.3	0

#	Article	IF	CITATIONS
127	Time for "Test and Treat―in Prevention of Mother-to-Child Transmission Programs in Low- and Middle-Income Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 287-289.	2.1	21
128	Treating HIV infection with drugs for HSV-2 infection?. Lancet, The, 2010, 375, 782-784.	13.7	4
129	Treatment of HIV infection with drugs for HSV-2 infection – Authors' reply. Lancet, The, 2010, 376, 88.	13.7	0
130	Combination therapy for visceral leishmaniasis. Lancet Infectious Diseases, The, 2010, 10, 184-194.	9.1	268
131	Substituting tenofovir for stavudine in resource-limited settings: there are challenges ahead. Aids, 2009, 23, 1027.	2.2	3
132	Is vitamin D deficiency involved in the immune reconstitution inflammatory syndrome?. AIDS Research and Therapy, 2009, 6, 4.	1.7	18
133	Fiveâ€year experience with scalingâ€up access to antiretroviral treatment in an HIV care programme in Cambodia. Tropical Medicine and International Health, 2009, 14, 1048-1058.	2.3	43
134	Substituting nevirapine for efavirenz: risk factors for toxicity in nonnaive patients in a resource-constrained setting. Aids, 2009, 23, 2374-2376.	2.2	5
135	An Algorithm to Optimize Viral Load Testing in HIV-Positive Patients With Suspected First-Line Antiretroviral Therapy Failure in Cambodia. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 40-48.	2.1	45
136	Validation of a Manual Blood System and the Distribution of Organisms Causing Bacteremia in a Resource-Limited Setting, SHCH, Phnom Penh, Cambodia. International Journal of Infectious Diseases, 2008, 12, e453.	3.3	0
137	Melioidosis in an Urban Referral Hospital, Phnom Penh, Cambodia. International Journal of Infectious Diseases, 2008, 12, e227.	3.3	Ο
138	Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infectious Diseases, The, 2008, 8, 516-523.	9.1	681
139	Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching. Aids, 2008, 22, 2053-2067.	2.2	26
140	Prevention and treatment of the immune reconstitution inflammatory syndrome. Current Opinion in HIV and AIDS, 2008, 3, 468-476.	3.8	22
141	Fever After a Stay in the Tropics: Clinical Spectrum and Outcome in HIV-Infected Travelers and Migrants. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 547-552.	2.1	21
142	HIV Viral Load Monitoring in Resource‣imited Regions: Optional or Necessary?. Clinical Infectious Diseases, 2007, 44, 128-134.	5.8	226
143	IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN AN HIV/TB CO-INFECTED PATIENT FOUR YEARS AFTER STARTING ANTIRETROVIRAL THERAPY. Acta Clinica Belgica, 2007, 62, 126-129.	1.2	21
144	Co-trimoxazole prophylaxis in tropical countries in the era of highly active antiretroviral therapy: do we know enough?. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, 101, 1059-1060.	1.8	6

#	Article	IF	CITATIONS
145	Bridging the gap between clinical practice and diagnostic clinical epidemiology: pilot experiences with a didactic model based on a logarithmic scale. Journal of Evaluation in Clinical Practice, 2007, 13, 374-380.	1.8	22
146	A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. Lancet Infectious Diseases, The, 2006, 6, 53-59.	9.1	59
147	Early Neuroschistosomiasis Complicating Katayama Syndrome. Emerging Infectious Diseases, 2006, 12, 1465-1466.	4.3	17
148	Changing Epidemiological and Clinical Aspects of Imported Malaria in Belgium. Journal of Travel Medicine, 2006, 8, 19-025.	3.0	8
149	Remote consultations and HIV/AIDS continuing education in low-resource settings. International Journal of Medical Informatics, 2006, 75, 633-637.	3.3	23
150	The Added Value of a CD4 Count to Identify Patients Eligible for Highly Active Antiretroviral Therapy Among HIV-Positive Adults in Cambodia. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 322-324.	2.1	19
151	Validation of Primary CD4 Gating as an Affordable Strategy for Absolute CD4 Counting in Cambodia. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 179-185.	2.1	19
152	Demographic and Clinical Characteristics of HIV-Infected Inpatients and Outpatients at a Cambodian Hospital. AIDS Patient Care and STDs, 2006, 20, 369-378.	2.5	8
153	Review editorial: Prevention of tuberculosis in resourceâ€poor countries with increasing access to highly active antiretroviral treatment. Tropical Medicine and International Health, 2005, 10, 1209-1214.	2.3	4
154	Comparison of albendazole regimen for prophylaxis of strongyloides hyperinfection in nephrotic syndrome patients on long-term steroids in Cambodia. Tropical Doctor, 2005, 35, 212-213.	0.5	4
155	Palliative care in sub-Saharan Africa. Lancet, The, 2005, 366, 546-547.	13.7	3
156	Disseminated nocardiosis presenting with cardiac tamponade in an HIV patient. International Journal of STD and AIDS, 2004, 15, 839-840.	1.1	6
157	Highly active antiretroviral treatment in countries with very limited resources: do we have cheaper alternatives?. International Journal of STD and AIDS, 2003, 14, 1-5.	1.1	2
158	PATIENTS WITH HIV INFECTION AND FEVER: A DIAGNOSTIC APPROACH. Acta Clinica Belgica, 2002, 57, 184-190.	1.2	12
159	Do Patents Prevent Access to Drugs for HIV in Developing Countries?. JAMA - Journal of the American Medical Association, 2002, 287, 840-843.	7.4	20
160	Splenic Rupture as a Complication of <i>P. Falciparum</i> Malaria After Residence in The Tropics. Report of Two Cases Acta Clinica Belgica, 1998, 53, 374-377.	1.2	11
161	A Cluster of Airport Malaria in Belgium in 1995 Acta Clinica Belgica, 1998, 53, 259-263.	1.2	21
162	Clinical algorithm for malaria in Africa. Lancet, The, 1996, 347, 1327-1328.	13.7	18